Table 2

Chromosomal aberrations in MSCs

Patient no.*DiagnosisCytogenetic markers
HCsMSCs
0806 AML M2 46,XX[25] t(1;2)(p32;q31)[15] 
1282 AML M5 47,XY,+8,t(11;19)(q23;p13.1)[25] t(1;6)(p32;p12)[23] 
0734 AML M1 46,XX,t(11;19)(q23;p13.1)[21]/46,XX[4] del(7)(q11.2q32)[9] 
0717 RA 46,XX[25] del(7)(q22)[3] 
0214 s-AML M6 46,XY,del(5)(q13q32)[25] del(7)(q22)[3] 
1068 AML M5 46,XY[25] t(3;20)(p13;p11.2)[15] 
0600 RAEB II 47,XY,+8[25] inv(X)(q12p22)[16] 
1150 s-AML M4 45,XY,−7[20]/46,XY[5] del(11)(q23)[2] 
0589 AML M4 46,XY[25] del(13)(q12q22)[6] 
0204 s-AML M1 46,XY,add(1)(p36),−4,der(5),der(7), der(9),add(12)(p13),der(17),+21[25] del(15)(q14)[4] 
1398 s-AML M2 46,XY[25], FLT3-ITD mutation +5[4] 
0816 RAEB II 46,XX,del(7)(q31)[25] +5[14] 
0645 RCMD-RS 46,XY[25] −4[6] 
0752 s-AML M1 46,XX,del(5)(q22q35)[8]/47,XX,idem, +21[3]/48,XX,idem,+21,+mar[6] −X[12] 
0789 RAEB I 46,XY[25] −Y[6] 
Patient no.*DiagnosisCytogenetic markers
HCsMSCs
0806 AML M2 46,XX[25] t(1;2)(p32;q31)[15] 
1282 AML M5 47,XY,+8,t(11;19)(q23;p13.1)[25] t(1;6)(p32;p12)[23] 
0734 AML M1 46,XX,t(11;19)(q23;p13.1)[21]/46,XX[4] del(7)(q11.2q32)[9] 
0717 RA 46,XX[25] del(7)(q22)[3] 
0214 s-AML M6 46,XY,del(5)(q13q32)[25] del(7)(q22)[3] 
1068 AML M5 46,XY[25] t(3;20)(p13;p11.2)[15] 
0600 RAEB II 47,XY,+8[25] inv(X)(q12p22)[16] 
1150 s-AML M4 45,XY,−7[20]/46,XY[5] del(11)(q23)[2] 
0589 AML M4 46,XY[25] del(13)(q12q22)[6] 
0204 s-AML M1 46,XY,add(1)(p36),−4,der(5),der(7), der(9),add(12)(p13),der(17),+21[25] del(15)(q14)[4] 
1398 s-AML M2 46,XY[25], FLT3-ITD mutation +5[4] 
0816 RAEB II 46,XX,del(7)(q31)[25] +5[14] 
0645 RCMD-RS 46,XY[25] −4[6] 
0752 s-AML M1 46,XX,del(5)(q22q35)[8]/47,XX,idem, +21[3]/48,XX,idem,+21,+mar[6] −X[12] 
0789 RAEB I 46,XY[25] −Y[6] 

RCMD indicates refractory cytopenia with multilineage dysplasia; and RCMD-RS, RCMD with ringed sideroblasts.

*

For the patient sample.

Close Modal

or Create an Account

Close Modal
Close Modal